Trump's NIH board plan puts $48B grants under White House veto

For legal and RegTech professionals, the story is less about science than about the administrative state: can the White House insert political appointees into a statutory grant-award process without Congress? The NIH's peer-review framework is codified; shifting final award authority to a board requiring unanimous OMB and NIH director approval may trigger Administrative Procedure Act challenges and appropriations fights.

The central development is a draft, not yet finalized, executive order directed by President Donald Trump that would create a White House board to approve individual National Institutes of Health grants. The Office of Management and Budget has been instructed to prepare the order. According to multiple reports, the proposed board would include OMB Director Russ Vought and NIH Director Jay Bhattacharya, with unanimous approval required for grant awards. That structural detail matters enormously: it would shift final authority over the NIH's $48 billion annual biomedical research budget from scientific peer-review panels, advisory councils, and agency officials to two political appointees. The directive reportedly followed a Friday Oval Office meeting on September 18, 2026, in which Bhattacharya declined Trump's request to cut Harvard University's NIH funding. The Office of Management and Budget is drafting the order, but it has not been issued or finalized. An HHS spokesperson said NIH grant money will be distributed, while OMB and the White House did not immediately comment.

“

The central development is a draft, not yet finalized, executive order directed by President Donald Trump that would create a White House board to approve individual National Institutes of Health grants.

The proposed shift must be understood against the NIH's existing statutory grant-making framework. For decades, research grant decisions have flowed through a dual peer-review system: scientific review groups evaluate technical merit, and advisory councils composed of scientists and public representatives make funding recommendations before agency officials award grants. This system was designed to insulate biomedical research from political pressure. A new board requiring unanimous approval from OMB and the NIH director would introduce a political veto point at the final stage of every award. Even if the NIH director remains a scientist, the OMB director is a political appointee whose role is ordinarily budget management, not scientific judgment. Unanimous approval means either member can block any grant, effectively giving OMB a per-grant veto over the entire $48 billion portfolio.

The immediate political context is a prior congressional confrontation. Congress earlier blocked an OMB plan to expand political review of federal health grants through mid-December. That episode suggests this new proposal will collide with existing appropriations language and legislative intent. The NIH's budget is appropriated by Congress, and lawmakers have consistently rejected efforts to politicize grant decisions. If the executive order is issued, it would likely face challenges under the Administrative Procedure Act, separation-of-powers principles, and the Impoundment Control Act, depending on whether the board actually withholds congressionally appropriated funds. A key legal question is whether the president can unilaterally restructure a statutory grant-award process without new legislation.